Skip to content

Claude Skills by dromlakhani

github.com/dromlakhani

877 skillsA× 8770 installs1,055 views

Cah Nbs 17ohp InterpretationAInterpret a newborn screening (NBS) 17-hydroxyprogesterone (17-OHP) result for congenital adrenal hyperplasia (CAH) — including gestational-age and birth-weight adjusted cut-offs, when to repeat, when to run a second-tier LC-MS/MS multi-steroid profile, which CAH subtypes the screen will and will not detect, and the immediate clinical action plan for a screen-positive baby. Use when a clinician asks "is this 17-OHP positive", "what to do with a high NBS 17-OHP", "screen-positive CAH next step...content-marketingreacttestingVotes: 0GitHub stars: 12
Cah Newborn Subtype DifferentiatorADifferentiate the seven enzymatic forms of congenital adrenal hyperplasia (CAH) presenting in the newborn or young infant — StAR (lipoid CAH), CYP11A1 (P450scc), HSD3B2 (3β-HSD), CYP17A1 (17α-hydroxylase/17,20-lyase), CYP21A2 (classic 21-hydroxylase), CYP11B1 (11β-hydroxylase), and POR (P450 oxidoreductase) — using biochemical pattern (renin, Na/K, BP, 17-OHP, DOC, androgens) plus genitalia phenotype in 46,XX and 46,XY infants. Use when a clinician asks "which type of CAH is this", "newborn w...documentationgoreactVotes: 0GitHub stars: 12
Genryzon Drug InteractionsADrug-interaction and co-medication adjustment reference for a child on Genryzon (somatrogon, weekly long-acting growth hormone). Covers glucocorticoids, insulin and oral hypoglycaemics, thyroxine, oral estrogen, and CYP3A4-metabolised drugs (sex steroids, corticosteroids, anticonvulsants, ciclosporin). Use when a clinician asks about drug interactions with Genryzon or somatrogon, prescribing another drug in a child on GH, girl on Genryzon starting OCP, diabetic child starting GH, adjusting hy...content-marketinggoexpressVotes: 0GitHub stars: 12
Genryzon Igf1 TitrationATitrate Genryzon (somatrogon, weekly long-acting growth hormone) dose in a paediatric GHD patient using serum IGF-1 SDS. Encodes the mandatory 4-days-post-dose sampling rule, the target SDS window, the 15% dose-reduction trigger, and the oral estrogen adjustment. Use when a clinician asks how to titrate somatrogon, when to sample IGF-1 on Genryzon, target IGF-1 SDS on weekly GH, what to do if IGF-1 is too high on somatrogon, IGF-1 rising on Genryzon, how to adjust GH dose in a girl started on...educationgoreactVotes: 0GitHub stars: 12
Genryzon Prescribing GuideABedside prescribing reference for Genryzon (somatrogon, Pfizer India) — the once-weekly long-acting growth hormone for paediatric growth hormone deficiency. Use when a clinician asks how to start Genryzon, how to dose somatrogon in a child, how to switch a child from daily growth hormone to weekly somatrogon, how to inject the Genryzon pen, missed-dose rule for somatrogon, when to stop somatrogon, or needs a monograph-level prescribing decision for a paediatric GHD patient. Applies to childre...content-marketinggorailsVotes: 0GitHub stars: 12
Genryzon Pretreatment ScreeningAPretreatment screening checklist before starting Genryzon (somatrogon, weekly long-acting growth hormone) in a child with confirmed paediatric growth hormone deficiency. Ensures thyroid, adrenal, glucose, ocular, tumour, and Prader-Willi status are checked before the first dose to prevent adrenal crisis, wasted therapy, unmasked hypothyroidism, unrecognised hyperglycaemia, missed intracranial hypertension, or sudden death in PWS. Use when a clinician asks what to check before starting somatro...researchgorailsVotes: 0GitHub stars: 12
Genryzon Red Flag MonitoringARed-flag safety scan for a child on Genryzon (somatrogon, weekly long-acting growth hormone) — recognise and act on the treatment-emergent adverse events that require holding, investigating, or stopping the drug. Covers benign intracranial hypertension, slipped capital femoral epiphysis, pancreatitis, injection-site myositis (m-cresol), scoliosis progression, second neoplasm surveillance in cancer survivors, hyperglycaemia unmasking, and adrenal insufficiency unmasking. Use when a clinician a...content-marketinggorailsVotes: 0GitHub stars: 12
Genryzon Treatment DiscontinuationADecide when to stop Genryzon (somatrogon, weekly long-acting growth hormone) in a paediatric GHD patient — the three physiological gates (epiphyseal closure, height velocity <2 cm/year, bone age >14 in girls or >16 in boys) plus the safety-driven stops (active tumour, adult GHD re-evaluation, adverse events). Use when a clinician asks when to stop somatrogon, when to discontinue Genryzon, is the child done with GH, has this child reached final height on GH, transitioning GH from paediatric to...content-marketinggoreactVotes: 0GitHub stars: 12
Es Gh Contraindication Spinal IrradiationAThis skill determines whether growth hormone (GH) treatment is contraindicated for short stature in childhood cancer survivors without confirmed growth hormone deficiency (GHD) who have a history of spinal irradiation (e.g., total-body irradiation, craniospinal irradiation). It is triggered by clinician questions such as "Can I use GH for short stature after spinal radiation?" or "Is GH appropriate for growth impairment post-CSI/TBI?"testinggorailsVotes: 0GitHub stars: 12
Es Gh Contraindication TkiAThis skill determines if growth hormone treatment should be avoided in childhood cancer survivors with short stature who are currently receiving tyrosine kinase inhibitor therapy (e.g., imatinib, dasatinib). Triggers include: “Should I use GH for short stature in a patient on imatinib?” or “Is GH safe with ongoing TKI therapy?”researchgorailsVotes: 0GitHub stars: 12
Es Gh Treatment OfferAThis skill determines whether growth hormone therapy should be initiated in childhood cancer survivors with confirmed growth hormone deficiency, based on demonstrated safety and efficacy in this population. Triggers include clinician questions such as "Should I start GH therapy for confirmed GHD?" or "Is growth hormone appropriate for this survivor with documented deficiency?"testinggorailsVotes: 0GitHub stars: 12
Es Gh Treatment Oncologist ConsultAThis skill determines when to discuss growth hormone treatment appropriateness and timing with the oncologist for childhood cancer survivors who have chronic stable disease (not definitively disease-free) following malignant disease treatment. Triggers include: "Should I involve oncology in GH decision for this survivor with stable disease?" or "Is oncologist input needed for GH timing in persistent disease?"blockchainrailsVotes: 0GitHub stars: 12
Es Gh Treatment RegimenAThis skill selects the appropriate growth hormone treatment regimen for childhood cancer survivors with confirmed growth hormone deficiency. It advises using the same dosing and monitoring strategies as for individuals with GHD from the noncancer population, triggered by questions such as “What GH dose and schedule should I use for this survivor?” or “How do I determine growth hormone therapy parameters in childhood cancer?”testinggorailsVotes: 0GitHub stars: 12
Es Gh Treatment TimingAThis skill determines the appropriate timing for initiating growth hormone (GH) therapy in childhood cancer survivors, recommending to wait until 1 year disease‑free after completion of malignant disease treatment to minimize risks. Triggers include clinician questions such as “When can I start GH therapy after cancer treatment completion?” or “How long should I wait to initiate growth hormone post‑remission?”testinggorailsVotes: 0GitHub stars: 12
Es Short Stature High Risk ScreenAThis skill identifies childhood cancer survivors at high risk for short adult height based on cranial/spinal/total body irradiation at a young age or a history of inadequate weight gain or prolonged steroid requirement. It is triggered by questions such as "Does this survivor need growth monitoring?" or "Is this patient high-risk for growth impairment?"ai-agentsrailsVotes: 0GitHub stars: 12
Es Sitting Height MeasurementAThis skill involves measuring standing and sitting height in childhood cancer survivors with spinal radiation exposure to assess for disproportionate short stature due to spinal foreshortening, including calculation of the upper-to-lower segment ratio. It is triggered by questions such as "How do I assess for spinal radiation impact on growth?" or "Should I measure sitting height in this survivor with chest/pelvis radiation?"documentationrailstestingVotes: 0GitHub stars: 12
Es Cpp Screening IndicationAThis skill identifies childhood cancer survivors who require periodic assessment for central precocious puberty based on history of hydrocephalus, intracranial tumors near the hypothalamic region, or hypothalamic‑pituitary axis radiation exposure. Triggers include clinician questions such as “Does this survivor need CPP evaluation?” or “Is central precocious puberty screening indicated?”.ai-agentsgorailsVotes: 0GitHub stars: 12
Es Cpp Treatment ApproachAThis skill determines the appropriate indications and treatment regimens for central precocious puberty in childhood cancer survivors, recommending to follow the same approaches (e.g., GnRHa therapy) used in the noncancer population. Triggers include: "How should I treat central precocious puberty in this survivor?" or "What GnRHa regimen is suitable for CPP in childhood cancer?"developmentgorailsVotes: 0GitHub stars: 12
Es Male Cpp Hormone TestAThis skill determines whether serum testosterone (preferably via LC-MS/MS) and luteinizing hormone levels should be obtained before 10:00 AM to support clinical evaluation of male childhood cancer survivors suspected of or at risk for central precocious puberty after gonadotoxic exposure. It is triggered by clinician questions such as "Should I check testosterone and LH for this boy at risk for early puberty after chemo?" or "Is morning hormone testing needed for CPP evaluation in males with ...ai-agentsgorailsVotes: 0GitHub stars: 12
Dbd Diabetes Hypertension Donor EligibilityADecide whether a kidney from a brain-dead deceased donor (DBD) with diabetes mellitus and/or hypertension is suitable for transplantation, using the ISOT 2025 Delphi consensus and Table 4 eligibility checklist. Trigger when a clinician asks "can I use a kidney from a diabetic deceased donor", "is this DBD with HTN/DM acceptable", "ECD donor with diabetes — accept or decline", "DBD eligibility for hypertensive donor", or shares a deceased donor with diabetes or hypertension and needs an accept...documentationrailsapiVotes: 0GitHub stars: 12
Mapi Score CalculatorACalculate the Maryland Aggregate Pathology Index (MAPI) on a deceased donor procurement kidney biopsy to predict graft survival and decide single vs dual vs discard allocation. Trigger when a clinician asks "what's the MAPI score", "interpret donor kidney biopsy", "should I use this marginal kidney", "MAPI cutoff for transplant", "procurement biopsy scoring", or has histology results from a deceased donor kidney and needs an objective grading.researchrailsapiVotes: 0GitHub stars: 12
Mirago Prescribing GuideAComplete bedside prescribing reference for Mirago (mirabegron, beta-3 adrenoceptor agonist) for overactive bladder — covering contraindications, safety screening, drug interactions, dose selection in special populations, titration, and administration. Use when a clinician asks how to start mirabegron, what dose to use in renal or hepatic impairment, is mirabegron safe in this patient, mirabegron drug interactions, or Mirago for OAB.content-marketinggoreactVotes: 0GitHub stars: 12
Cac Scoring Indication Interpretation 2026ADecide when to order coronary artery calcium (CAC) scoring in a primary-prevention patient and interpret the result per the 2026 ACC/AHA multisociety dyslipidaemia guideline. Covers the Class 1 indication (men ≥40 / women ≥45, borderline / intermediate PREVENT-ASCVD risk, uncertainty about LLT), CAC score interpretation (0, 1–99, 100–299, ≥300, ≥1000), how CAC modifies LDL and non-HDL goals, when to repeat CAC, and pitfalls (incidental CAC on non-cardiac CT, radiation, cost). Use when a clini...developmentgorailsVotes: 0GitHub stars: 12
Dyslipidemia Cpr Framework 2026AWork a primary-prevention patient through the 2026 ACC/AHA multisociety dyslipidaemia guideline CPR framework — Calculate (10-year and 30-year PREVENT-ASCVD), Classify (low / borderline / intermediate / high), Personalize (demographic, clinical, biomarker, and reproductive risk enhancers), and Reclassify (coronary artery calcium scoring where appropriate). Use when a clinician asks how to assess ASCVD risk for primary prevention, who needs a statin, borderline risk patient what to do, interme...educationgorailsVotes: 0GitHub stars: 12
Dyslipidemia Ldl Treatment Goals 2026ASet absolute LDL-C, non-HDL-C, and ApoB treatment goals, PLUS percent LDL-C reduction, for a primary-prevention patient on lipid-lowering therapy per the re-introduced treatment goals in the 2026 ACC/AHA multisociety dyslipidaemia guideline. Covers goals by PREVENT-ASCVD category (low / borderline / intermediate / high), by CAC score, in severe hypercholesterolaemia / FH, in diabetes with multiple ASCVD risk factors, and the ApoB targets once LDL-C and non-HDL-C goals are met. Use when a clin...businessgorailsVotes: 0GitHub stars: 12
Lpa Screening Interpretation CascadeAOrder and interpret lipoprotein(a) [Lp(a)] measurement at least once in a lifetime, apply the risk-enhancer threshold (≥125 nmol/L or ≥50 mg/dL), and run cascade screening of first-degree relatives for premature ASCVD, familial hypercholesterolaemia, or elevated Lp(a) per the 2026 ACC/AHA multisociety dyslipidaemia guideline. Covers the Class 1 lifetime measurement, how elevated Lp(a) affects LLT initiation and intensification, the cascade screening indications, the interaction of Lp(a) with ...businessgorailsVotes: 0GitHub stars: 12
Prevent Ascvd Risk Calculator InterpretationACalculate and interpret the PREVENT-ASCVD risk score (10-year and 30-year) for primary prevention of atherosclerotic cardiovascular disease per the 2026 ACC/AHA multisociety dyslipidaemia guideline. Covers inputs required, risk-category thresholds (low <3%, borderline 3–<5%, intermediate 5–<10%, high ≥10%), when to use the 30-year calculation (adults 30–59), and how PREVENT differs from the older Pooled Cohort Equations (lower risk estimates by 40–50%, race-agnostic). Use when a clinician ask...developmentgorailsVotes: 0GitHub stars: 12

Claude Skills by dromlakhani — 877 skills, security-graded | Skills Directory